Comments on ICER’s Draft Evidence Report: Acute Treatment for Migraine
December 5, 2019
Migraine is a disabling condition for far too many Americans. Effective migraine control can meaningfully improve the quality of life for patients living with this disease, and can also provide offsetting health care savings. It is imperative that the any cost-effectiveness evaluation accounts for the full benefits enabled by medicines that offer effective migraine control.
Yet the methodology employed by ICER’s draft evidence report undervalues the benefits of a more effective migraine treatment, commits methodological errors and relies on questionable assumptions.
Categorized in: Analysis